Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All favipiravir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand

Rattanaumpawan et al., Antibiotics, doi:10.3390/antibiotics11060805
Jun 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 63 hospitalized patients in Thailand treated with favipiravir showing a lower favipiravir loading dose negatively associated with clinical improvement.
Rattanaumpawan et al., 15 Jun 2022, retrospective, Thailand, peer-reviewed, 5 authors. Contact: pinyo.rat@mahidol.ac.th (corresponding author), jsupunee@yahoo.com, ornmd@live.com, nattawan.pala@gmail.com, ooyaoi@hotmail.com.
This PaperFavipiravirAll
Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand
Pinyo Rattanaumpawan, Supunnee Jirajariyavej, Kanokorn Lerdlamyong, Nattawan Palavutitotai, Jatuporn Saiyarin
Antibiotics, doi:10.3390/antibiotics11060805
Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for treating COVID-19 are limited. We conducted a retrospective observational study of hospitalized adult patients with COVID-19 at five tertiary care hospitals in Thailand. We reviewed patient charts to obtain all necessary data. Among 247 COVID-19 patients, 63 (23.0%) received ≥1 dose of favipiravir. Of these 63 patients, 61.9% were male with a median age of 48 years (range 22-85 years), 27.0% required an O 2 nasal cannula, 9.5% required non-invasive ventilation and/or high-flow O 2 therapy, and 6.4% required invasive mechanical ventilation and/or ECMO. The median baseline NEWS2 score was 5 (0-16). The Day-7 clinical improvement rate [95%CI] was 66.7% [53.7-78.0%] in all patients, 92.5% [75.7-99.1%] in patients who did not require O 2 supplementation, and 47.2% [0.4-64.5%] in patients who required O 2 supplementation. No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%. A multivariate analysis revealed three poor prognostic factors for Day-7 clinical improvement (odds ratio (95%CI); p-value): older age (0.94 (0.89-0.99); p = 0.04), a higher baseline NEWS2 score (0.64 (0.47-0.88); p = 0.006), and a lower favipiravir loading dose (≤45 mg/kg/day) (0.04 (0.005-0.4); p = 0.006). In conclusion, our study reports the promising effectiveness of favipiravir for treating COVID-19 patients. In addition to older age and a high baseline NEWS2 score, a low loading dose of favipiravir (≤45 mg/kg/day) was also identified as a poor prognostic factor for early clinical improvement. Further studies to explore the optimal dose and the optimal timing of drug initiation for favipiravir should be performed.
Author Contributions: Conceptualization, P.R.; methodology, P.R., investigation, S.J., K.L., N.P. and J.S.; writing-original draft preparation, P.R., S.J., K.L., N.P. and J.S.; writing-review and editing, P.R., funding acquisition, P.R. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by Siriraj Research Fund, Grant number (IO) R016333038, Faculty of Medicine Siriraj Hospital, Mahidol University. The APC was funded by Faculty of Medicine Siriraj Hospital, Mahidol University. Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of all involved hospitals. The Siriraj IRB approved the protocol on 1 May 2020 (certification of approval number: Si 357/2020). Informed Consent Statement: Written inform consent was waived due to a retrospective study design. Conflicts of Interest: The authors declare no conflict of interest.
References
Bai, Mu, Kargbo, Song, Niu et al., Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, Clin. Infect. Dis, doi:10.1093/cid/ciw571
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19-Preliminary Report, N. Engl. J. Med, doi:10.1056/NEJMoa2007764
Bosaeed, Alharbi, Mahmoud, Alrehily, Bahlaq et al., Efficacy of favipiravir in adults with mild COVID-19: A randomized, double-blind, multicentre, placebocontrolled clinical trial, Clin. Microbiol. Infect, doi:10.1016/j.cmi.2021.12.026
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering, doi:10.1016/j.eng.2020.03.007
Chen, Huang, Cheng, Wu, Chen et al., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, doi:10.1101/2020.03.17.20037432
Chen, Zhang, Huang, Yin, Cheng et al., Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial, Front. Pharmacol, doi:10.3389/fphar.2021.683296
Chuah, Chow, Hor, Cheng, Ker et al., Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial, Clin. Infect. Dis, doi:10.1093/cid/ciab962
Dabbous, El-Sayed, El Assal, Elghazaly, Ebeid et al., Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial, Sci. Rep, doi:10.1038/s41598-021-98683-5
Doi, Hibino, Hase, Yamamoto, Kasamatsu et al., Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19, Antimicrob. Agents Chemother, doi:10.1128/AAC.01897-20
Fischer, Eron, Jr, Holman, Cohen et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci. Transl. Med, doi:10.1126/scitranslmed.abl7430
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc. Jpn. Acad. Ser. B, doi:10.2183/pjab.93.027
Gottlieb, Vaca, Paredes, Mera, Webb et al., Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N. Engl. J. Med, doi:10.1056/NEJMoa2116846
Goyal, Choi, Pinheiro, Schenck, Chen et al., Clinical Characteristics of Covid-19 in New York City, N. Engl. J. Med, doi:10.1056/NEJMc2010419
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy, JAMA, doi:10.1001/jama.2020.5394
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Hung, Ghula, Aziz, Makram, Tawfik et al., The efficacy and adverse effects of favipiravir on patients with COVID-19: A systematic review and meta-analysis of published clinical trials and observational studies, Int. J. Infect. Dis
Mahase, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, BMJ, doi:10.1136/bmj.n2713
Manaf, Nitya, Dhuha, Abdulkarim, Fatema et al., Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease, Sci. Rep, doi:10.1038/s41598-022-08794-w
Nguyen, Guedj, Anglaret, Laouenan, Madelain et al., Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLOS Negl. Trop. Dis, doi:10.1371/journal.pntd.0005389
Pavan, Saiprasad, Akash, Akash, Aneesh et al., Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting, Int. J. Gen. Med, doi:10.2147/IJGM.S349241
Udwadia, Singh, Barkate, Patil, Rangwala et al., Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial, Int. J. Infect. Dis, doi:10.1016/j.ijid.2020.11.142
Wang, Fan, Salam, Horby, Hayden et al., Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection, J. Infect. Dis, doi:10.1093/infdis/jiz656
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Zhao, Zhang, Zhu, Chen, Chen et al., Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial, Int. Immunopharmacol, doi:10.1016/j.intimp.2021.107702
{ 'indexed': {'date-parts': [[2022, 6, 16]], 'date-time': '2022-06-16T03:13:08Z', 'timestamp': 1655349188417}, 'reference-count': 25, 'publisher': 'MDPI AG', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2022, 6, 15]], 'date-time': '2022-06-15T00:00:00Z', 'timestamp': 1655251200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'name': 'Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand', 'award': ['R016333038']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity ' 'against SARS-CoV-2. Presently, data on the real-world effectiveness and optimal dosage of ' 'favipiravir for treating COVID-19 are limited. We conducted a retrospective observational ' 'study of hospitalized adult patients with COVID-19 at five tertiary care hospitals in ' 'Thailand. We reviewed patient charts to obtain all necessary data. Among 247 COVID-19 ' 'patients, 63 (23.0%) received ≥1 dose of favipiravir. Of these 63 patients, 61.9% were male ' 'with a median age of 48 years (range 22–85 years), 27.0% required an O2 nasal cannula, 9.5% ' 'required non-invasive ventilation and/or high-flow O2 therapy, and 6.4% required invasive ' 'mechanical ventilation and/or ECMO. The median baseline NEWS2 score was 5 (0–16). The Day-7 ' 'clinical improvement rate [95%CI] was 66.7% [53.7–78.0%] in all patients, 92.5% [75.7–99.1%] ' 'in patients who did not require O2 supplementation, and 47.2% [0.4–64.5%] in patients who ' 'required O2 supplementation. No life-threatening adverse events were identified. The 28-day ' 'mortality rate was 4.8%. A multivariate analysis revealed three poor prognostic factors for ' 'Day-7 clinical improvement (odds ratio (95%CI); p-value): older age (0.94 (0.89–0.99); p = ' '0.04), a higher baseline NEWS2 score (0.64 (0.47–0.88); p = 0.006), and a lower favipiravir ' 'loading dose (≤45 mg/kg/day) (0.04 (0.005–0.4); p = 0.006). In conclusion, our study reports ' 'the promising effectiveness of favipiravir for treating COVID-19 patients. In addition to ' 'older age and a high baseline NEWS2 score, a low loading dose of favipiravir (≤45 mg/kg/day) ' 'was also identified as a poor prognostic factor for early clinical improvement. Further ' 'studies to explore the optimal dose and the optimal timing of drug initiation for favipiravir ' 'should be performed.</jats:p>', 'DOI': '10.3390/antibiotics11060805', 'type': 'journal-article', 'created': {'date-parts': [[2022, 6, 16]], 'date-time': '2022-06-16T02:17:01Z', 'timestamp': 1655345821000}, 'page': '805', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results ' 'from a Multicenter Observational Study in Thailand', 'prefix': '10.3390', 'volume': '11', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2964-6732', 'authenticated-orcid': False, 'given': 'Pinyo', 'family': 'Rattanaumpawan', 'sequence': 'first', 'affiliation': []}, {'given': 'Supunnee', 'family': 'Jirajariyavej', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kanokorn', 'family': 'Lerdlamyong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nattawan', 'family': 'Palavutitotai', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jatuporn', 'family': 'Saiyarin', 'sequence': 'additional', 'affiliation': []}], 'member': '1968', 'published-online': {'date-parts': [[2022, 6, 15]]}, 'reference': [ { 'key': 'ref1', 'unstructured': 'WHO Coronavirus (COVID-19) Dashboard\nhttps://covid19.who.int/'}, {'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007764'}, {'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)31022-9'}, {'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/bmj.n2713'}, {'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2116846'}, {'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/scitranslmed.abl7430'}, {'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.93.027'}, {'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciw571'}, {'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eng.2020.03.007'}, {'key': 'ref10', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.03.17.20037432'}, {'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2021.683296'}, {'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/cid/ciab962'}, {'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-021-98683-5'}, {'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.11.142'}, {'key': 'ref15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.intimp.2021.107702'}, {'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cmi.2021.12.026'}, {'key': 'ref17', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.01897-20'}, {'key': 'ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-022-08794-w'}, {'key': 'ref19', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/IJGM.S349241'}, {'key': 'ref20', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2022.04.035'}, {'key': 'ref21', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiz656'}, {'key': 'ref22', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pntd.0005389'}, {'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30183-5'}, {'key': 'ref24', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.5394'}, {'key': 'ref25', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2010419'}], 'container-title': 'Antibiotics', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.mdpi.com/2079-6382/11/6/805/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 6, 16]], 'date-time': '2022-06-16T02:28:14Z', 'timestamp': 1655346494000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.mdpi.com/2079-6382/11/6/805'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 6, 15]]}, 'references-count': 25, 'journal-issue': {'issue': '6', 'published-online': {'date-parts': [[2022, 6]]}}, 'alternative-id': ['antibiotics11060805'], 'URL': 'http://dx.doi.org/10.3390/antibiotics11060805', 'relation': {}, 'ISSN': ['2079-6382'], 'subject': [ 'Pharmacology (medical)', 'Infectious Diseases', 'Microbiology (medical)', 'General Pharmacology, Toxicology and Pharmaceutics', 'Biochemistry', 'Microbiology'], 'container-title-short': 'Antibiotics', 'published': {'date-parts': [[2022, 6, 15]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit